GDTC Stock Summary and Trading Ideas (Cytomed Therapeutics Limited - | NASDAQ:GDTC)

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Cytomed Therapeutics Limited - trades on the NASDAQ stock market under the symbol GDTC.

As of November 6, 2026, GDTC stock price declined to $0.86 with 9,293 million shares trading.

GDTC has a beta of -0.25, meaning it tends to be less sensitive to market movements. GDTC has a correlation of 0.00 to the broad based SPY ETF.

GDTC has a market cap of $10.16 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, GDTC traded as high as $5.50 and as low as $.68.

GDTC has underperformed the market in the last year with a price return of -59.3% while the SPY ETF gained +9.6%. However, in the short term, GDTC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +2.3% vs -4.2% return in SPY. But in the last 2 weeks, GDTC shares have been beat by the market, returning -6.5% compared to an SPY return of -3.8%.

GDTC support price is $.77 and resistance is $.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GDTC shares will trade within this expected range on the day.